Eight clinical variables - measurable or self-reported - drive the dysgeusia experience. Each variable activates one or more of four pathophysiological mechanisms identified in §02. Each mechanism maps to one or more of the four SuzChews ingredient strategies. This section traces that three-stage pipeline from biomarker to mouth.
The literature review in §02 identified four distinct mechanisms that co-produce dysgeusia. But mechanisms do not switch on uniformly: which mechanism dominates depends on which clinical variables are present in a given patient. Iron-heavy chemotherapy regimens amplify metallic taste via metal-ion binding; platinum-based agents elevate carbonyl production via lipid peroxidation; poor oral hygiene worsens all of them.
The pipeline is therefore three stages: Biomarker → Mechanism → Ingredient Strategy. Stage one is what the clinician or patient knows or can measure. Stage two is what is biologically happening at the oral epithelium and taste receptor cells. Stage three is what SuzChews does about it. The diagram in Fig. 04.1 makes the full mapping explicit. The §05 algorithm translates that diagram into a per-patient formulation recommendation.
Variable 01
Elevated iron worsens metallic taste during chemotherapy. Iron-containing compounds - particularly those found in red meat - amplify the taste distortions already present in chemo patients, contributing to a bitter or metallic sensation during eating 7. The mechanism is additive to the metal-ion binding already caused by platinum-class drugs.
The gum cannot remove dietary iron. What it can do: the trigeminal stimulation strategy (menthol, carbonation) redirects sensory attention away from the metallic signal through the anatomically separate trigeminal pathway, and the umami bitter masker provides competitive distraction at the bitter and metallic receptor sites. In the §05 algorithm, elevated iron is the primary driver of trigeminal and umami ingredient intensity.
Variable 02
Zinc deficiency is independently linked to taste disorders. Your literature review identified zinc as a major variable: zinc levels in cancer patients frequently drop during treatment due to reduced dietary intake and increased cellular demand 12. The effect compounds the taste-bud apoptosis pathway: fewer functional receptors and reduced cofactor availability.
Sour taste detection is more resilient to overall receptor compromise than sweet or salt perception. The sour/tart strategy therefore functions as a reliable flavor anchor for zinc-deficient patients - delivering a strong, recognizable signal even when the broader receptor system is compromised.
Variable 03
Reactive carbonyls produced by lipid peroxidation generate the bitter and rancid quality of dysgeusia - active bad signal, not just absent good signal. Platinum-based agents oxidize oral epithelial cell membranes through lipid peroxidation, releasing reactive carbonyl compounds that bind to taste receptor sites 8 and generate bitter and rancid perception independent of whatever the patient is eating.
This is why simply flooding the mouth with pleasant flavors is insufficient. The umami bitter masker - savory peptides competing for the same receptor sites - is the targeted response. The trigeminal stimulant provides the complementary redirect: while the umami peptides compete at the receptors, menthol and carbonation pull sensory attention through the separate trigeminal pathway.
Variable 04
Among chemotherapeutic agents with the highest rates of producing dysgeusia are anthracyclines, paclitaxel, carboplatin, and docetaxel 5. Counter-intuitively, cisplatin and 5-fluorouracil are less likely to cause taste alterations despite cisplatin's known metallic-binding profile. Taxane-class agents produce the most severe dysgeusia when it does occur.
Treatment type is a covariate, not a sufficient predictor. A patient on carboplatin with good oral hygiene and normal iron may experience milder dysgeusia than a patient on docetaxel with poor hygiene and deficient zinc. The §05 algorithm weights treatment type as one of six inputs - a strong signal, but not a stand-alone determinant.
Variable 05
Oral hygiene is one of the most modifiable variables in the dysgeusia severity equation. The Canadian Cancer Society literature links poor oral health - smoking, tobacco use, irregular brushing, existing mouth disease - to significantly worse dysgeusia outcomes during treatment 11. Compromised oral tissue is more vulnerable to taste-bud apoptosis and creates a less stable salivary environment for delivering whatever tastant signal remains.
In the §05 algorithm, oral hygiene acts as a global intensity multiplier rather than activating a specific strategy - because it amplifies whichever mechanism is already dominant. Poor oral hygiene: ×1.18 on all ingredient intensities. Fair oral hygiene: ×1.09. Good oral hygiene: baseline.
Variable 06 (measurement instrument)
The CiTAS scale (Kano version, 18-item self-report) 3 does double duty in this framework: it is both the field's standard measurement instrument and the algorithm's primary patient-state input. Its three dimensions are each diagnostically informative:
Dimension I (quantitative: hypogeusia, ageusia) → signals taste-bud apoptosis dominance → sour/tart strategy weighted up. Dimension II (qualitative: heterogeusia, cacogeusia, metallic) → signals metallic/carbonyl pathway dominance → trigeminal + umami weighted up. Dimension III (nutrition-related effects: difficulty eating hot/fatty foods) → signals nausea co-morbidity → anti-nausea support weighted up. This makes the CiTAS score not just a measurement but a formulation routing signal.
Summary
| Variable | Measurement | Primary mechanism activated | Ingredient strategy driven | Status |
|---|---|---|---|---|
| Iron Levels | Serum ferritin or dietary proxy | Metal-ion binding | Trigeminal · Umami | Confirmed |
| Zinc Levels | Serum zinc or dietary proxy | Taste-bud apoptosis (compounded) | Sour / Tart · Anti-nausea | Confirmed |
| Carbonyl Risk | Proxy: platinum agent use | Lipid peroxidation | Umami · Trigeminal | Confirmed |
| Treatment Type | Regimen classification | Multiple - mechanism varies by drug class | Varies (see §05) | Confirmed |
| Oral Hygiene | Self-report / clinical record | Magnitude amplifier across all mechanisms | Global multiplier | Confirmed |
| CiTAS Score | 18-item Likert self-report | Dimensional decomposition of which mechanism dominates | Dimension-matched (see §05) | Confirmed |
| Age | Chronological | Taste-bud fragility (fully mediated) | Captured by CiTAS - redundant | Dropped |
| Disease History | Comorbidity record | None independent of treatment | n/a | Dropped |
Each biomarker in the framework routes to a defined set of functional ingredients - not generic flavorings, but compounds selected for a mechanistic reason tied to what that biomarker tells us about the patient's taste-disruption pathway. Below is the full ingredient-biomarker mapping as it currently stands.
Iron (elevated serum ferritin / dietary proxy). The metallic signal produced by iron-amplified metal-ion binding at taste receptors is addressed through two mechanisms simultaneously. Menthol (0.1–0.4% w/w) activates TRPM8 cold-sensitive channels via the trigeminal nerve - a separate sensory pathway that competes with and partially overrides the metallic signal without requiring taste receptor function. Glutamate-rich savory peptides (hydrolyzed vegetable protein fraction, ~0.5–1.2% w/w) occupy bitter and metallic receptor sites, reducing the intensity of the iron-driven signal 7.
Zinc (deficient). Zinc deficiency compounds taste-bud apoptosis by reducing cofactor availability in gustatory signaling. The most resilient taste modality under receptor compromise is sour. Citric acid (0.4–0.9% w/w) and malic acid (0.2–0.5% w/w) deliver a reliable sour anchor that remains perceptible even when sweet and salt detection are blunted 12. Anti-nausea co-support (ginger extract, standardized 5% gingerols) addresses the nausea co-morbidity that frequently accompanies zinc deficiency during treatment.
Carbonyl production / Platinum agent use. Reactive carbonyls generated by lipid peroxidation bind taste receptors and generate active bitter-rancid signal. The targeted response is competitive displacement: savory peptides (glutamate + IMP synergy) occupy the same receptor sites, reducing carbonyl signal intensity 8. Trigeminal stimulation (menthol, carbonation agent) provides a parallel sensory redirect for the residual metallic component.
Treatment type - drug-class routing. Platinum-based regimens (cisplatin, carboplatin, oxaliplatin): maximum trigeminal + umami loading. Taxane-class (paclitaxel, docetaxel): elevated sour intensity to target the severe dysgeusia profile; moderate trigeminal. Anthracyclines: anti-nausea support weighted highest, with vitamin B6 (pyridoxine, 2–5 mg per piece) and magnesium gluconate included for nausea-pathway support 5.
What the model doesn't yet address. Peripheral and central neuropathy blocking cranial-nerve taste transmission (the §02 fifth mechanism) is outside the scope of a topical oral intervention - the gum does not address this pathway, and the algorithm does not attempt to 9. The umami-carbonyl competitive-displacement claim is mechanistically consistent with bitter-receptor pharmacology but has not been demonstrated directly in a chemo-patient cohort. That experiment is the single most important target for a future validation study. Algorithm weights in §05 are calibrated from the literature, not derived from regression on patient outcome data.
Model boundaries
Neuropathy-pathway disruption is outside the gum's intervention scope. The umami competitive-displacement mechanism needs direct clinical validation. Ingredient concentrations shown here are formulation targets based on literature - not outputs of a completed clinical trial. These boundaries define exactly what a Phase I/II trial would need to measure.